← Back to Search

PD-L1 Inhibitor

Durvalumab for Lung Cancer (ATLANTIC Trial)

Phase 2

Waitlist Available

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged at least 18 years

Patient's tumour sample must be PD-L1 positive (≥25% of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3)

Must not have

Prior exposure to any anti-PD-1 or anti-PD-L1 antibody

Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from date of first treatment until final dco (up to approximately 3 years 8 months)

Awards & highlights

No Placebo-Only Group

Summary

This trial will study the effects of the drug durvalumab in patients with non small cell lung cancer that has spread to other parts of the body. The trial will assess how well the drug works, as well as its safety and tolerability.

Who is the study for?

This trial is for adults over 18 with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have already tried a platinum-based chemotherapy and one other treatment without success. They should be relatively healthy (WHO Performance Status of 0 or 1), expected to live more than 12 weeks, and their tumors must show certain levels of PD-L1 protein.

What is being tested?

The study tests the effects of MEDI4736 (Durvalumab), focusing on how well it works, its safety, and how tolerable it is for patients with NSCLC that's either locally advanced or has spread to other parts of the body.

What are the potential side effects?

Possible side effects include immune system reactions that can affect organs, infusion-related reactions similar to allergic responses, fatigue, digestive issues like diarrhea or constipation, skin problems like rash or itching, and potential increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My tumor is PD-L1 positive with specific levels of cell staining.

Select...

My lung cancer is at an advanced stage (IIIB or IV).

Select...

I am fully active or able to carry out light work.

Select...

My NSCLC has worsened after platinum-based chemo and another treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been treated with drugs targeting PD-1 or PD-L1 before.

Select...

I don't have severe side effects from past cancer treatments.

Select...

I do not have severe illnesses or uncontrolled diseases like active infections.

Select...

I do not have uncontrolled heart issues or high blood pressure.

Select...

I have had severe side effects from previous immunotherapy.

Select...

I have or had Crohn's disease or ulcerative colitis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from date of first treatment until final dco (up to approximately 3 years 8 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from date of first treatment until final dco (up to approximately 3 years 8 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of first treatment until final dco (up to approximately 3 years 8 months) for reporting.